INVESTORS
11 px font size 12 px font size 14 px font size
ASX Announcements
Annual Report
Background Materials
FAQs
Glossary
Corporate Governance
Investor Contact
APOLLO NEWSLETTER
Professor Paul
Zimmet AO
Head of
International Diabetes Institute, Melbourne
"The data that I have seen so far makes this one of the most forward looking and best prospects of an oral insulin"
Click here to see Paul Zimmet's view on Apollo's oral insulin
Bill Moss AM
Non-Executive Director and
Investor
"Apollo has a number of opportunities to grow into the future. Opportunities perhaps that are much greater than many other companies many times their size"
Click here to hear Bill Moss's view on investing in Apollo
Background Materials
Therapeutics click to download pdf
Contents
  • Description
  • Therapeutics development pipeline
  • Competitive advantages of Apollo?s therapeutics
  • Advantages of biotherapeutics
Transdermal delivery click to download pdf
Contents
  • Technology
  • Benefits
  • Competitive advantages
  • Advantages of Transdermal Delivery
Natural human proteins click to download pdf
Contents
  • Technology
  • Benefits
  • Competitive advantages
  • More closely mimic human proteins
  • Contain human sugar attachments (glycosylation)
  • Technical appendix
    • Techniques for obtaining human proteins
    • Post-translational modifications (attachments)
    • Effect of source cell species on attachments
    • Glycosylation (sugar structures)
    • Roles of glycosylation
Research proteinsclick to download pdf
Contents
  • Description
  • Benefits of Apollo’s hcx™ proteins
  • Competitive advantages of Apollo’s hcx™ proteins
  • Product matrix: Human proteins for research use
  • Comparison of cell source for three large competitors
  • Relative advantages of research protein products
  • Examples of benefits of hcx™ proteins
  • Vascular Endothelial Growth Factor (VEGF)
  • Interleukin 2